GSK announces FIRST trial met its primary endpoint of progression free survival in ovarian cancer
GSK plc (LSE/NYSE: GSK) announced headline results from the FIRST-ENGOT-OV44 phase III…
Search
Have an existing account?
Sign In
Tag: FIRST-ENGOT-OV44